Cryo-Cell International Inc (CCEL)
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$4.28+0.94%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Cryo-Cell is improving its operating income, rising to $765,134 in 2026-Q1 from a loss of nearly $4 million in 2025-Q4. The company aims to regain compliance with NYSE listing standards, which would stabilize its market presence. Analysts expect revenue to grow slightly by 0.5% next year. These signs show progress in fixing the business.
The company remains loss-making and faces regulatory risks from past delisting notices. Revenue growth is minimal, and the stock has fallen 13% from its high. If operating income fails to improve or compliance is not regained, the turnaround may stall.
The market expects almost no revenue growth and reflects the company's current loss-making status. Our view aligns with this cautious outlook but sees potential if operating income continues to improve and regulatory compliance is achieved.
Breaks if: operating income falls below $0 in any quarter next year
Breaks if: failure to regain compliance by end of 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CCEL represents a turnaround investment with a focus on improving operating income. The current thesis state is intact, as recent financial results are strong, although the company remains loss-making overall.
The market appears to have a neutral view on CCEL's valuation, with expectations aligned with its recent performance. There is a low level of fragility in the current market regime, indicating that the stock is not overly sensitive to sudden changes.
Management is actively working to improve operating income, which has shown notable improvement recently. However, the company faces high risk due to potential earnings misses, especially given its erratic earnings history.
The long-term thesis hinges on the performance of sector bellwethers like HCA, THC, and EHC, which could influence CCEL's momentum. Additionally, the company's ability to regain compliance with NYSE listing standards will be crucial.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Implement and execute the compliance plan to meet NYSE American LLC continued listing standards.
Stated as a priority in 2 of last 2 quarters. Management received a notice of non-compliance in 2026-Q1 and submitted a compliance plan accepted by NYSE American in 2026-Q2. The trajectory shows active regulatory engagement but no financial metrics directly tied to compliance progress.
“Received notice from NYSE Regulation accepting the Company's plan to regain compliance with listing standards.”
“Received written notice from NYSE American indicating non-compliance with continued listing standards.”
Breaks if: revenue growth falls below 0% in FY27
In the next 1 to 3 years, CCEL's trajectory will depend on both sector performance and internal operational improvements. Not investment advice.